• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    L Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender Offer

    10/13/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THRN alert in real time by email

    NEW YORK, Oct. 13, 2023 /PRNewswire/ -- L Catterton and Thorne HealthTech, Inc. ("Thorne") (NASDAQ:THRN) today announced that the tender offer to purchase all of the issued and outstanding shares of Thorne's common stock ("Shares") for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended (such date and time, the "Expiration Time").

    Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised L Catterton that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly withdrawn in the Offer, representing 97.3% of the issued and outstanding Shares as of the Expiration Time. Accordingly, all conditions to the Offer have been satisfied. L Catterton and its affiliate, Healthspan Merger Sub, Inc. ("Purchaser"), will promptly accept for payment, and will promptly pay for, all Shares validly tendered and not validly withdrawn in the Offer.

    The parties expect to consummate the acquisition on October 16, 2023, in accordance with, and subject to the terms of, the definitive agreement for the proposed acquisition.

    Advisors

    BofA Securities served as financial advisor and Kirkland & Ellis LLP served as legal advisor to L Catterton. CG Sawaya Partners (operating under Canaccord Genuity) served as exclusive financial advisor and Wilson Sonsini Goodrich & Rosati served as legal advisor to Thorne and Thorne's Special Committee of the Board of Directors.

    About L Catterton

    L Catterton is a market-leading consumer-focused investment firm, managing approximately $34 billion of equity capital and three multi-product platforms: private equity, credit, and real estate. Leveraging deep category insight, operational excellence, and a broad network of strategic relationships, L Catterton's team of more than 200 investment and operating professionals across 17 offices partners with management teams to drive differentiated value creation across its portfolio. Founded in 1989, the firm has made over 250 investments in some of the world's most iconic consumer brands. For more information about L Catterton, please visit www.lcatterton.com.

    About Thorne HealthTech, Inc.

    Thorne is a leader in developing innovative solutions for delivering personalized approaches to health and wellness. As a science-driven wellness company that empowers individuals with the support, education, and solutions they need to achieve healthy aging – living healthier longer – Thorne utilizes testing and data to create improved product efficacy and to deliver personalized solutions to consumers, health professionals, and corporations. Predicated on the power of the individual, Thorne leverages artificial intelligence models to provide insights and personalized data, products, and services that help individuals take a proactive and actionable approach to improve and maintain their health over a lifetime. Thorne is the only supplement manufacturer that collaborates with Mayo Clinic on health and wellness research and content and is trusted by more than five million customers, 47,000+ health-care professionals, thousands of professional athletes, more than 100 professional sports teams, and multiple U.S. National Teams. For more information, visit www.thorne.com.

    Additional Information and Where to Find It

    This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that affiliates of L Catterton, including Purchaser, filed with the U.S. Securities and Exchange Commission (the "SEC"). The solicitation and offer to buy outstanding Shares of Thorne was only made pursuant to the tender offer materials that affiliates of L Catterton, including Purchaser, filed with the SEC. The tender offer materials are available for free on the SEC's website at www.sec.gov.

    Forward-Looking Statements

    This communication contains forward-looking statements. All statements other than statements of historical facts contained in this communication are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. Forward-looking statements contained in this communication include, but are not limited to, statements regarding Thorne's pending acquisition by affiliates of L Catterton (the "Transaction"), including the expected timing of the closing of the Transaction. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include risks associated with potential litigation relating to the Transaction; uncertainties as to the timing of the consummation of the Transaction and the ability of each party to consummate the Transaction; and the risks and uncertainties described in the section titled "Risk Factors" and elsewhere in Thorne's filings made with the SEC, including its Annual Report on Form 10-K filed on March 31, 2023, and its subsequent Quarterly Reports on Form 10-Q and other SEC filings, copies of which are available free of charge on the SEC's website at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. All forward-looking statements in this communication are based on information available as of the date of this communication, and neither L Catterton nor Thorne assumes any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date of this communication, except as required by law.

    Contacts:

    L Catterton:

    Julie Hamilton

    [email protected]

    Thorne:

    Jordan Fisher

    [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/l-catterton-and-thorne-healthtech-inc-announce-expiration-of-tender-offer-301956100.html

    SOURCE L Catterton

    Get the next $THRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THRN

    DatePrice TargetRatingAnalyst
    11/17/2022$5.50Buy
    Canaccord Genuity
    10/18/2021$11.00Buy
    B of A Securities
    10/18/2021Buy
    BofA Securities
    10/18/2021$13.00Outperform
    Evercore ISI Group
    10/18/2021$11.00Outperform
    Cowen & Co.
    10/18/2021$11.00Outperform
    RBC Capital
    More analyst ratings

    $THRN
    SEC Filings

    View All

    SEC Form 15-12G filed by Thorne Healthtech Inc.

    15-12G - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/26/23 6:03:57 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Thorne Healthtech Inc.

    S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/16/23 4:54:57 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Thorne Healthtech Inc.

    S-8 POS - Thorne Healthtech, Inc. (0001844280) (Filer)

    10/16/23 4:53:59 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    L Catterton and Thorne HealthTech, Inc. Announce Expiration of Tender Offer

    NEW YORK, Oct. 13, 2023 /PRNewswire/ -- L Catterton and Thorne HealthTech, Inc. ("Thorne") (NASDAQ:THRN) today announced that the tender offer to purchase all of the issued and outstanding shares of Thorne's common stock ("Shares") for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes (the "Offer"), expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended (such date and time, the "Expiration Time"). Computershare Trust Company, N.A., the depositary and paying agent for the Offer, has advised L Catterton that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly

    10/13/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lifshitz Law PLLC Announces Investigations of ABCM, THRN, BHRB, and AGE

    NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Abcam Plc (NASDAQ:ABCM) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of ABCM to Danaher Corporation for $24.00 per share in cash for each share of ABCM common stock owned. If you are an ABCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Thorne HealthTech, Inc. (NASDAQ:THRN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of TRHN to L Catter

    9/2/23 7:47:00 PM ET
    $ABCM
    $BHRB
    $THRN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Banks
    Finance

    Thorne HealthTech, Inc. Enters into Definitive Agreement to be Acquired by L Catterton for $10.20 Per Share in Cash

    L Catterton to Commence a Tender Offer for all of Thorne's Outstanding Shares of Common Stock Thorne Stockholders to Receive $10.20 per Share in Cash, Representing a 94% Premium to the Unaffected Price Independent Special Committee and Thorne Board of Directors Unanimously Approve Transaction and Recommend that All Stockholders Tender Their Shares in the Tender Offer  NEW YORK, Aug. 28, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused inv

    8/28/23 8:00:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Varma Saloni S. returned 581,643 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 5:01:44 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mckenna Thomas P. returned 1,172,227 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 5:00:39 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mccamy William C. returned 589,804 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Thorne Healthtech, Inc. (0001844280) (Issuer)

    10/18/23 4:59:36 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Thorne HealthTech with a new price target

    Canaccord Genuity initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $5.50

    11/17/22 7:24:31 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B of A Securities initiated coverage on Thorne HealthTech with a new price target

    B of A Securities initiated coverage of Thorne HealthTech with a rating of Buy and set a new price target of $11.00

    10/18/21 10:22:55 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Thorne HealthTech

    BofA Securities initiated coverage of Thorne HealthTech with a rating of Buy

    10/18/21 9:20:07 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Leadership Updates

    Live Leadership Updates

    View All

    Thorne HealthTech Appoints Saloni Varma as New Chief Financial Officer

    NEW YORK, March 13, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne" or "Thorne HealthTech") (NASDAQ:THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced that it has appointed Saloni Varma as Chief Financial Officer (CFO). As CFO, Varma will lead all aspects of the company's Accounting and Finance functions including budgeting planning and analysis, accounting, SEC reporting, tax, treasury, and investor relations. Varma brings more than 20 years of experience across a range of consumer goods companies, mos

    3/13/23 7:30:00 AM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Financials

    Live finance-specific insights

    View All

    Thorne HealthTech Reports Second Quarter 2023 Results

    Record Net Sales With Growth of 33.1%; Raises Full-Year Guidance Midpoints for Net Sales and Gross Margin NEW YORK, Aug. 8, 2023  /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the second quarter ended June 30, 2023. Second Quarter Highlights: Net sales grew 33.1% year-over-year to $72.7 million, with direct-to-consumer ("DTC") sales growth of 39.3%Gross profit grew 35.7% year-over-year to $40.6 million; gross profit as a % of net sales increased year-over-year to 55.9%.Net incom

    8/8/23 4:05:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thorne HealthTech Schedules Second Quarter 2023 Earnings Release and Conference Call for August 8

    Company Withdraws Participation in the Canaccord Genuity 43rd Annual Growth Conference on Aug. 10 NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, will release its second quarter 2023 financial results after market close on Tuesday, Aug. 8, 2023. The company will host a conference call to discuss its results on Tuesday, Aug. 8, 2023, at 5:00 p.m. (U.S. Eastern Time). A live webcast and replay of the call will be available on the investors section of the

    8/1/23 5:15:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thorne HealthTech Reports First Quarter 2023 Results

    Net Sales Growth of 20.7%; Reaffirms Full-Year 2023 Guidance NEW YORK, May 11, 2023 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech", "Thorne" or the "Company") (NASDAQ:THRN), a leader in delivering personalized, innovative solutions that empower individuals to live healthier, longer lives, today announced its financial results for the first quarter ended March 31, 2023. First Quarter Highlights: Net sales grew 20.7% year-over-year to $65.2 million, with direct-to-consumer ("DTC") sales growth of 41.0%Gross profit grew 16.3% year-over-year to $34.3 million; gross p

    5/11/23 4:05:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    11/6/23 3:57:00 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    10/17/23 4:10:56 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)

    SC 13G/A - Thorne Healthtech, Inc. (0001844280) (Subject)

    2/10/23 5:04:59 PM ET
    $THRN
    Biotechnology: Pharmaceutical Preparations
    Health Care